Abstract
Curia plans to spend $35 million to expand the capacity of its facility in Rensselaer, New York. The contract development and manufacturing organization, known until recently as AMRI, aims to more than double the site’s batch production capability for small-molecule active pharmaceutical ingredients (APIs), allowing it to meet growing demand for highly potent APIs. The expansion is expected to be completed in 18 months. Curia has several facilities in the US, as well as plants in France, Spain, Italy, and India.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
